In addition, MEG3 was found to activate cisplatin-induced cellular pyroptosis by promoting NLRP3/caspase-1/GSDMD axis, implying that MEG3 could be effective therapeutic target of breast cancer [49]. This evidence concerns the gene GSDMD and breast carcinoma.